DelveInsight's Non-Cystic Fibrosis Bronchiectasis Market Report provides comprehensive insights into the epidemiology and market dynamics across the 7MM. LAS VEGAS ...

A unique identifier (the Central Population Registry number ... Respiratory diseases were further categorised by type (COPD, asthma, pneumoconiosis, bronchiectasis, cystic fibrosis, previous ...

The drug inhibits a novel target to reduce levels of inorganic pyrophosphate (PPi), a key metabolite central to the ... the first approved therapy for bronchiectasis in the US.

There was no underlying bronchiectasis. The consolidation was visible on the ... with extensive FDG-avidity and a large area of central necrosis (figure 1B). There was a broad area of contact with the ...

Stifel analysts maintained their Buy rating on Insmed shares (NASDAQ:INSM) and increased the price target from $88.00 to $97.00. According to InvestingPro data, the stock has delivered an impressive ...

Patients in China with bronchiectasis in lower- vs higher-income regions are younger and have more severe disease, exacerbations, and respiratory comorbidities. Patients in China with bronchiectasis ...

Permanent changes such as bronchiectasis may persist. ABPA: Allergic bronchopulmonary aspergillosis; GINA: Global initiative for asthma. Adapted with permission from [7]. ABPA-S Fulfils the ...

Brensocatib, if approved, would be the first available treatment specifically targeting bronchiectasis, a chronic lung disease that currently has no FDA-approved therapies in the U.S. The drug is also ...

Background: The prevalence of bronchiectasis among adult Aboriginal Australians is higher than that of non-Aboriginal Australians. However, despite evidence to suggest higher prevalence of ...

Central Cee and 21 Savage are watching the price go all the way up on their new song, “GBP.” Over a beat of atmospheric synths and punchy drums, Central Cee leans into the transatlantic nature ...

Officer of Insmed Inc. (NASDAQ:INSM), recently sold a significant portion of the company's stock according to a new SEC filing. The transactions, executed on February 10, 2025, were carried out under ...

Bronchiectasis is the abnormal dilation of the airway which may be caused by various etiologies in children. Beyond the more recognized cause of bacterial and viral infections and primary ...